Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab

Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases

(2017) John A. Hamilton et al.   NATURE REVIEWS DRUG DISCOVERY

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis

(2017) Michael E. Weinblatt et al.   Arthritis & Rheumatology

FRI0216 Long-Term Safety and Efficacy of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, in Patients with Rheumatoid Arthritis

(2016) G. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Pathogenic IL-23 signaling is required to initiate GM-CSF-driven autoimmune myocarditis in mice

(2016) Lei Wu et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung

(2016) Jamie Campbell et al.   mAbs

Conformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor Signaling

(2016) Sophie E. Broughton et al.   STRUCTURE

Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma

(2016) Nestor A Molfino et al.   BMJ Open

GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential

(2015) John A Hamilton   Expert Review of Clinical Immunology

The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity

(2015) Andrew L. Croxford et al.   IMMUNITY

Targeting GM-CSF in inflammatory diseases

(2015) Ian P. Wicks et al.   Nature Reviews Rheumatology

Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis

(2015) Luca Piccoli et al.   Nature Communications

MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

(2014) Frank Behrens et al.   ANNALS OF THE RHEUMATIC DISEASES

Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis

(2014) D E A Greven et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study

(2014) Tsutomu Takeuchi et al.   Modern Rheumatology

Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety

(2014) Patricia C. Ryan et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages

(2014) Shicheng Su et al.   OncoImmunology

Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain

(2012) Andrew D Cook et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy

(2012) L. van de Laar et al.   BLOOD

Colony stimulating factors and myeloid cell biology in health and disease

(2012) John A. Hamilton et al.   TRENDS IN IMMUNOLOGY

Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development

(2012) Andrew D Cook et al.   ARTHRITIS RESEARCH & THERAPY

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor- , in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

(2011) G. R. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Regulation of systemic and local myeloid cell subpopulations by bone marrow cell-derived granulocyte-macrophage colony-stimulating factor in experimental inflammatory arthritis

(2011) Andrew D. Cook et al.   ARTHRITIS AND RHEUMATISM

RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation

(2011) Laura Codarri et al.   NATURE IMMUNOLOGY

The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner

(2010) Kevin D. Deane et al.   ARTHRITIS AND RHEUMATISM

The molecular basis of pulmonary alveolar proteinosis

(2010) Brenna Carey et al.   CLINICAL IMMUNOLOGY

Hematopoietic cytokines

(2008) D. Metcalf   BLOOD

The Structure of the GM-CSF Receptor Complex Reveals a Distinct Mode of Cytokine Receptor Activation

(2008) Guido Hansen et al.   CELL

GM-CSF mediates autoimmunity by enhancing IL-6–dependent Th17 cell development and survival

(2008) Ivo Sonderegger et al.   JOURNAL OF EXPERIMENTAL MEDICINE